Insider · CIK 0001110744

Hassan Fred

Reports to the SEC for 12 companies · PALO ALTO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001110744

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-22	BBIOBridgeBio Pharma, Inc.A Award	Director	AAward	+3,990 sh	—	—	29,879
2026-06-22	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+5,277 sh	—	—	5,277
2026-03-13	PGENPRECIGEN, INC.M Exercise/Conversion	Director	MExercise/Conversion	+71.8K sh	—	—	1,243,239
2026-03-13	PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−71.8K sh	—	—	0
2026-03-10	PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award	Director	AAward	+41.1K sh	—	—	41,073
2026-03-10	PGENPRECIGEN, INC. · Restricted Stock UnitsA Award	Director	AAward	+35.6K sh	—	—	35,612
2026-03-10	PGENPRECIGEN, INC.A Award	Director	AAward	+17.9K sh	$3.51	+$63K	1,171,400
2026-01-09	COCPCocrystal Pharma, Inc. · Stock Options (Right to Buy)A Award	Director	AAward	+16.4K sh	—	—	16,410
2026-01-02	EYPTEyePoint, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2025-10-28	COCPCocrystal Pharma, Inc.A Award	Director	AAward	+360K sh	$1.39	+$500K	1,383,009
2025-10-28	COCPCocrystal Pharma, Inc. · WarrantsA Award	Director	AAward	+719K sh	$1.39	+$1M	719,426
2025-06-20	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,425 sh	—	—	8,425
2025-06-20	BBIOBridgeBio Pharma, Inc.A Award	Director	AAward	+6,589 sh	—	—	25,889
2025-03-14	PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−87.4K sh	—	—	0
2025-03-14	PGENPRECIGEN, INC.M Exercise/Conversion	Director	MExercise/Conversion	+87.4K sh	—	—	1,153,452
2025-03-13	PGENPRECIGEN, INC. · Restricted Stock UnitsA Award	Director	AAward	+71.8K sh	—	—	71,839
2025-03-13	PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award	Director	AAward	+83.5K sh	—	—	83,517
2025-03-13	PGENPRECIGEN, INC.A Award	Director	AAward	+36.2K sh	$1.74	+$63K	1,066,040
2025-01-03	EYPTEyePoint, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2024-10-09	COCPCocrystal Pharma, Inc.A Award	Director	AAward	+8,067 sh	—	—	1,023,296
2024-09-03	EYPTEyePoint, Inc. · Stock Options (Right to buy)A Award	Director	AAward	+60K sh	—	—	60,000
2024-06-21	BBIOBridgeBio Pharma, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+26K sh	—	—	26,014
2024-03-14	PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award	Director	AAward	+102K sh	—	—	101,626
2024-03-14	PGENPRECIGEN, INC.A Award	Director	AAward	+44.1K sh	$1.43	+$63K	1,029,834
2024-03-14	PGENPRECIGEN, INC. · Restricted Stock UnitsA Award	Director	AAward	+87.4K sh	—	—	87,412
2024-03-09	PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−107K sh	—	—	0
2024-03-09	PGENPRECIGEN, INC.M Exercise/Conversion	Director	MExercise/Conversion	+107K sh	—	—	985,779
2023-08-14	PGENPRECIGEN, INC.P Purchase	Director	PPurchase	+570K sh	$1.75	+$998K	878,942
2023-07-18	COCPCocrystal Pharma, Inc. · Stock Options (Right to Buy)A Award	Director	AAward	+7,333 sh	—	—	7,333
2023-06-21	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+51.5K sh	—	—	51,501
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−2,123 sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−541 sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−40K sh	—	—	0
2023-05-19	Prometheus Biosciences, Inc.A Award	Director	AAward	+2,123 sh	—	—	2,123
2023-03-09	PGENPRECIGEN, INC.A Award	Director	AAward	+48.3K sh	$1.17	+$56.5K	308,597
2023-03-09	PGENPRECIGEN, INC. · Restricted Stock UnitsA Award	Director	AAward	+107K sh	—	—	106,837
2023-03-09	PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award	Director	AAward	+125K sh	—	—	125,489
2023-02-22	PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−61.6K sh	—	—	0
2023-02-22	PGENPRECIGEN, INC.M Exercise/Conversion	Director	MExercise/Conversion	+61.6K sh	—	—	260,307
2022-06-22	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+105K sh	—	—	104,921
2022-05-19	Prometheus Biosciences, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+21K sh	—	—	21,013
2022-03-25	PGENPRECIGEN, INC.M Exercise/Conversion	Director	MExercise/Conversion	+16.2K sh	—	—	198,731
2022-03-25	PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−16.2K sh	—	—	0
2022-02-22	PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award	Director	AAward	+83.2K sh	—	—	83,189
2022-02-22	PGENPRECIGEN, INC.A Award	Director	AAward	+27.8K sh	$2.03	+$56.5K	182,519
2022-02-22	PGENPRECIGEN, INC. · Restricted Stock UnitsA Award	Director	AAward	+61.6K sh	—	—	61,576
2021-12-29	BBIOBridgeBio Pharma, Inc.P Purchase	Director	PPurchase	+19.3K sh	$14.17	+$273K	19,300
2021-11-14	Prometheus Biosciences, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+541 sh	—	—	541
2021-08-17	BBIOBridgeBio Pharma, Inc. · Stock Option (right to buy)A Award	Director	AAward	+49.9K sh	—	—	49,869

Recent filings

Accepted (ET)
Jun 244
Hassan Fred0001470831-26-000629
SEC(opens sec.gov)
Mar 164
Hassan Fred0000950103-26-003833
SEC(opens sec.gov)
Mar 124
Hassan Fred0000950103-26-003687
SEC(opens sec.gov)
Jan 134
Hassan Fred0001493152-26-002037
SEC(opens sec.gov)
Jan 64
Hassan Fred0001110744-26-000002
SEC(opens sec.gov)
Oct 304
Hassan Fred0001493152-25-020221
SEC(opens sec.gov)
Jun 244
Hassan Fred0000950170-25-089647
SEC(opens sec.gov)
Mar 174
Hassan Fred0000950103-25-003518
SEC(opens sec.gov)
Jan 74
Hassan Fred0001562180-25-000235
SEC(opens sec.gov)
Oct 114
Hassan Fred0001493152-24-040899
SEC(opens sec.gov)

Companies

Address

C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250

PALO ALTO, CA, 94304